Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

132 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Quality of Life Following Receipt of Adjuvant Chemotherapy With and Without Bevacizumab in Patients With Lymph Node-Positive and High-Risk Lymph Node-Negative Breast Cancer.
Rosenberg SM, O'Neill A, Sepucha K, Miller KD, Dang CT, Northfelt DW, Sledge GW, Schneider BP, Partridge AH. Rosenberg SM, et al. Among authors: schneider bp. JAMA Netw Open. 2022 Feb 1;5(2):e220254. doi: 10.1001/jamanetworkopen.2022.0254. JAMA Netw Open. 2022. PMID: 35226083 Free PMC article. Clinical Trial.
Angiogenesis of breast cancer.
Schneider BP, Miller KD. Schneider BP, et al. J Clin Oncol. 2005 Mar 10;23(8):1782-90. doi: 10.1200/JCO.2005.12.017. J Clin Oncol. 2005. PMID: 15755986 Review. No abstract available.
Association of polymorphisms of angiogenesis genes with breast cancer.
Schneider BP, Radovich M, Sledge GW, Robarge JD, Li L, Storniolo AM, Lemler S, Nguyen AT, Hancock BA, Stout M, Skaar T, Flockhart DA. Schneider BP, et al. Breast Cancer Res Treat. 2008 Sep;111(1):157-63. doi: 10.1007/s10549-007-9755-9. Epub 2007 Sep 20. Breast Cancer Res Treat. 2008. PMID: 17891484
Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100.
Schneider BP, Wang M, Radovich M, Sledge GW, Badve S, Thor A, Flockhart DA, Hancock B, Davidson N, Gralow J, Dickler M, Perez EA, Cobleigh M, Shenkier T, Edgerton S, Miller KD; ECOG 2100. Schneider BP, et al. J Clin Oncol. 2008 Oct 1;26(28):4672-8. doi: 10.1200/JCO.2008.16.1612. J Clin Oncol. 2008. PMID: 18824714 Free PMC article. Clinical Trial.
Triple-negative breast cancer: risk factors to potential targets.
Schneider BP, Winer EP, Foulkes WD, Garber J, Perou CM, Richardson A, Sledge GW, Carey LA. Schneider BP, et al. Clin Cancer Res. 2008 Dec 15;14(24):8010-8. doi: 10.1158/1078-0432.CCR-08-1208. Clin Cancer Res. 2008. PMID: 19088017 Review.
132 results